BNTC

Benitec Biopharma Inc. (NASDAQ:BNTC) is a development-stage biotechnology company founded in 1995 and headquartered in Hayward, California. The company went public in 2014 and focuses on developing novel genetic medicines using proprietary DNA-directed RNA interference (ddRNAi) technology. As a clinical-stage biotech firm, Benitec has built its pipeline around treating rare genetic diseases and chronic viral infections through innovative gene therapy approaches.